Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04403204
Other study ID # D20057
Secondary ID 1R01AR077157-01
Status Recruiting
Phase
First received
Last updated
Start date September 14, 2020
Est. completion date May 31, 2025

Study information

Verified date February 2024
Source Dartmouth-Hitchcock Medical Center
Contact Jon Mikael Anderson
Phone 603-653-3306
Email jon.mikael.anderson@hitchcock.org
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The focus of this prospective observational study is to (1) establish the range and variation associated with bone/soft tissue perfusion in fracture patients, using ICG fluorescence imaging; (2) examine the relationship between perfusion and complications such as surgical site infection (SSI), persistent SSI, and fracture nonunion; (3) to determine whether the quantitative ICG fluorescence can be used to guide bony debridement in the setting of infected fracture to minimize complications.


Description:

This will be a prospective observational trial to better understand the range and variation associated with bone/soft tissue perfusion in fracture patients and examine the relationship between perfusion, measured using quantitative Indocyanine green (ICG) fluorescence and complications such as surgical site infection (SSI), persistent SSI, and fracture nonunion. Primary outcome measure is complication (either infection, recurrent infection or nonunion). Eligible consenting patients will receive standard of care treatment for their fracture or infection including irrigation and debridement of their operative site and/or fracture fixation. After exposure, 0.1 mg/Kg ICG will be injected intravenously and video rate ICG fluorescence images will be acquired 20 seconds before and 4 minutes after the injection, each before and after debridement. A subset of 30 post-fracture complication patients will undergo surgical treatment for their infection in Center of Innovation Surgery (CIS) and have either an intraoperative Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) after exposure but before the ICG injection or a preoperative DCE-MRI. Patients receiving surgery in the CIS will be required to sign an additional CIS-specific consent document. The need for repeat surgical procedure will be left up to the treating surgeon. If repeat procedure is needed, pre- and post-debridement quantitative ICG fluorescence images will be obtained at each procedure. Study participants will be followed at 2 weeks, 6 weeks, 3 months, 6 months, and one year from their index study surgery. Complication including index infection, recurrent infection or delaying union/nonunion will be identified at the time of diagnosis and/or during each participants assessment that occurs during routine outpatient clinic visit. Detailed information on the infection including date of diagnosis, participant signs and symptoms, culture test results, method of treatment(s), and date of resolution will be documented.


Recruitment information / eligibility

Status Recruiting
Enrollment 170
Est. completion date May 31, 2025
Est. primary completion date May 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Established SSI Fracture (Cohort Cohort 1, Group 1) 1. Patients 18 years of age or older. 2. Extremity fracture. 3. Prior definitive fracture management with external fixation, internal fixation, or joint fusion. 4. Superficial, deep, or organ space SSI (as per CDC criteria) at the fracture site that requires operative management. 5. Will have all fracture care surgeries performed by a participating surgeon or delegate. 6. Provision of informed consent. Subset: DCE-MRI (Cohort 1-1, Group 2) 1. Patients 18 years of age or older. 2. Closed extremity fracture. 3. Planned definitive fracture management with external fixation, internal fixation, or joint fusion. 4. Will have all planned fracture care surgeries performed by a participating surgeon or delegate. 5. Provision of informed consent. Exclusion Criteria: Established SSI Fracture Cohort (Cohort 1, Group 1) 1. Fracture of the hand. 2. Iodine allergy. 3. Received previous surgical debridement to manage the SSI. 4. Incarceration. 5. Problems, in the judgment of study personnel, with maintaining follow-up with the patient. Subset: DCE-MRI (Cohort 1-1, Group2) 6. the presence of an electronic implant, such as a pacemaker 7. the presence of a metal implant, such as an aneurysm clip 8. the presence of other contraindication(s), as determined by the MRI technologists and radiologists. 9. A history of allergy to iodides 10. A GFR < 30 ml/min as determined by blood test on the day of NIR/MR imaging, or from lab results within 3 months of DCE-MRI for this study

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Immunofluorescence Imaging
Patients will be administered FDA approved ICG through intravenous injection and imaged by a FDA approved surgical microscope (Spy Elite) which is 0.5 meter away from the subject. Both ICG fluorescence and the two imaging systems have been used for routine clinical practice for many years. Figure (a) shows the Schematic sketch of the imaging systems. ICG fluorescence imaging utilizes intravenously injected ICG, which is a fluorescent dye that is FDA-approved for clinical use, illuminated with near-infrared light. The ICG dye is indirectly activated and the dynamic fluorescence due to bone perfusion can be captured by a video rate imaging system.
DCE-MRI
Characterize the relationship between bone perfusion as quantified by ICG based DCE-FI and DCE-MRI in human patients to develop an accurate depth-sensitive fluorescence imaging model that will correct for the surface-weighted feature of fluorescence imaging

Locations

Country Name City State
United States University of Maryland, Baltimore R. Adams Cowley Shock Trauma Baltimore Maryland
United States Brigham and Women's Hospital Boston Massachusetts
United States University of California, Irvine Irvine California
United States Dartmouth Hitchcock Medical Center Lebanon New Hampshire

Sponsors (6)

Lead Sponsor Collaborator
Dartmouth-Hitchcock Medical Center Brigham and Women's Hospital, Dartmouth College, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), University of California, Irvine, University of Maryland, Baltimore

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients experiencing post procedure surgical site infections Post-procedure surgical site infection using CDC criteria will be documented at each follow-up appointment up to one year 1 year
Primary Number of patients requiring unplanned fracture-related reoperations All unplanned reoperations will be documented 1 year
See also
  Status Clinical Trial Phase
Completed NCT04567901 - GNRI and Influence of Nutrition on the Mortality of Trauma Patients
Enrolling by invitation NCT05794165 - Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism Phase 2
Not yet recruiting NCT06326827 - In'Oss™ (MBCP® Putty) Ortho
Completed NCT04913402 - Sufentanil Used by Paramedics to Treat Pain in Acute Trauma
Not yet recruiting NCT06070350 - Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children Phase 3
Recruiting NCT05616130 - Pathological Myeloid Activation After Sepsis and Trauma
Completed NCT05628519 - Captain Sonar Impact on Trauma Patient Management N/A
Recruiting NCT04907240 - Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry
Recruiting NCT06123104 - Assessment of Automatic Tourniquets for Soldiers During Wartime N/A
Recruiting NCT05865327 - UltrasouNd-guided Percutaneous Intercostal Nerve Cryoneurolysis for Analgesia Following Traumatic Rib Fracture N/A
Completed NCT05175872 - Factors Affecting Mortality and Morbidity in Trauma Patients Followed in Intensive Care Unit
Not yet recruiting NCT04387305 - Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children: An Efficacy Study Phase 3
Recruiting NCT04416412 - ICG Fluorescence Imaging in Open Fracture Trauma Patients
Completed NCT04080479 - Bolus Versus Continuous Enteral Tube Feeding N/A
Completed NCT04030832 - Reconstruction of Skin Substance Loss With "Micro-grafts" Obtained by Mechanical Disintegration
Active, not recruiting NCT06063434 - Testing the Effectiveness of Night Shift, a Theory-based Customized Video Game N/A
Not yet recruiting NCT04954768 - Epidemiological Characteristics of Elderly Trauma Patients in Zhejiang Province and Development of Geriatric Trauma Short-term Mortality Prediction Model
Completed NCT04327895 - Surgery in Context of Terrorist Attack : a Survey of French Surgeons
Completed NCT03888703 - The Use of Fractional Ablative CO2 Laser vs Control on Acute Traumatic Injuries to Prevent Scar Formation N/A
Active, not recruiting NCT05873959 - An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular Trauma